Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment
This is a non-significant risk, double-blinded, randomized, registrational study to compare the effectiveness of two digital, software only, medical devices (SaMD) (attune™ and cerena™) in reducing cancer-related anxiety and depression symptoms when used adjunctively with multidisciplinary (medical, psychosocial) oncology usual care regimens for up to 10 weeks. Study population will consist of up to 553 participants with stage I-III breast cancer or stage I-III NSCLC. The primary endpoint is percent improvement in anxiety symptoms at Week 10 and secondary endpoints of percent improvement in depressive symptoms will be assessed at Week 12. An interim analysis for efficacy and futility will be conducted once 236 participants have completed the study.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 13, 2022 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Blue Note Therapeutics
- Interventions being studied
- Device: Attune™; Device: Cerena™
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Stage I-III breast cancer or Stage I-III NSCLC who are currently in active treatment or have completed initial cancer directed treatments (surgery, radiation, chemotherapy) within the past 3 months;
- Are experiencing at least moderate anxiety (GAD-7 \>10) or mild-to-moderate depression (PHQ-8 score 5-11);
- Are fluent in English; and
- Have access to smartphone, or tablet capable of running iOS or Android software.
- Previous history of cancer;
- \<2-yr survival prognosis as determined by treating clinician;
- Currently participating in investigative CBT trial for treatment of anxiety or depression;
- Participant is unable to complete training, has cognitive deficits, more severe psychiatric conditions, lack of access to internet accessible device or psycho-social conditions (e.g., other social conditions, that would interfere with adherence to self-directed care), such that in investigator's opinion the participant would be unable to complete the study;
- Recently completed use of Blue Note Therapeutics Covid Cancer Care Program or other Blue Note Therapeutics-sponsored study; and
- PHQ-9 Q9 response \>0 AND Columbia Suicide Severity Risk Scale (or equivalent) score of Category 2- "suicidal ideation" at screening.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- OPN HealthcareGlendale, California
- Oncology Physicians Network HealthcareLos Alamitos, California
- Redlands OncologyRedlands, California
- Eastern CT Hematology and Oncology AssociatesNorwich, Connecticut
- Illinios Cancer CarePeoria, Illinois
- Massachusetts General HospitalBoston, Massachusetts
- Rogel Cancer Center | University of MichiganAnn Arbor, Michigan
- SCL HealthBillings, Montana
- New Jersey Center for Cancer ResearchBrick, New Jersey
- New York Cancer & Blood SpecialistsPort Jefferson Station, New York
- Tri-County Hematology and Oncology-MassillonMassillon, Ohio
- MD AndersonHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 13, 2022. Always confirm current availability with the study team.